[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596117":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":83,"collaborators":86,"id":90,"slug":91,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":92,"sex":97,"minAge":98,"maxAge":25,"enrollmentInfo":99,"targetDuration":25,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":37,"whyStopped":25,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo: Control","PLACEBO_COMPARATOR","Participants with Hypertensive disorders of pregnancy will receive placebo equivalent capsules to self-administer daily over the 12-week duration of the study treatment.",[13],"Drug: Placebo tablet to match spironolactone",{"label":15,"type":16,"description":17,"interventionNames":18},"Treatment: Spironolactone","EXPERIMENTAL","Participants with hypertensive disorders of pregnancy will receive 25mg capsules of spironolactone to self-administer daily over the 12-week duration of the study treatment.",[19],"Drug: spironolactone 25 mg orally once daily",[21,26],{"type":22,"name":23,"description":17,"armGroupLabels":24,"otherNames":25},"DRUG","spironolactone 25 mg orally once daily",[15],null,{"type":22,"name":27,"description":11,"armGroupLabels":28,"otherNames":25},"Placebo tablet to match spironolactone",[9],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Michael C Honigberg, MD, MPP","CONTACT","617-726-1843","mhonigberg@mgh.harvard.edu",[36,56,67],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-71.05977,42.35843,{"lat":47,"lon":46},[50,54],{"name":51,"role":32,"phone":52,"phoneExt":25,"email":53},"Victoria R Viscosi, MS","617-724-2996","vviscosi@mgh.harvard.edu",{"name":31,"role":55,"phone":25,"phoneExt":25,"email":25},"PRINCIPAL_INVESTIGATOR",{"facility":57,"status":37,"city":38,"state":39,"zip":58,"country":41,"countryCode":42,"cosmosGeoPoint":59,"geoPoint":61,"contacts":62},"Brigham and Women's Hospital","02115",{"type":44,"coordinates":60},[46,47],{"lat":47,"lon":46},[63],{"name":64,"role":32,"phone":65,"phoneExt":25,"email":66},"Maria A. Pabon, MD","857-407-4561","mpabonporras@bwh.harvard.edu",{"facility":68,"status":69,"city":70,"state":71,"zip":72,"country":41,"countryCode":42,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"University of Pittsburgh Magee-Womens Hospital","NOT_YET_RECRUITING","Pittsburgh","Pennsylvania","15213",{"type":44,"coordinates":74},[75,76],-79.99589,40.44062,{"lat":76,"lon":75},[79],{"name":80,"role":32,"phone":81,"phoneExt":25,"email":82},"Malamo E Countouris, MD, MS","412-569-4229","countourisme@upmc.edu",{"type":55,"investigatorFullName":84,"investigatorTitle":85,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Michael C. Honigberg","Principal Investigator",[87,88],{"name":57,"class":6},{"name":89,"class":6},"University of Pittsburgh Medical Center","100596117","phase-2-spironolactone-to-improve-pregnancy-associated-hypertension-trajectories-100596117",false,"NCT07041281","Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories","IMPACT-HT","Inclusion Criteria:\n\n* Females aged ≥18 years\n* HDP (gestational hypertension or preeclampsia) without pre-pregnancy chronic hypertension\n* BMI ≥25 kg\u002Fm2 prior to pregnancy or in the first trimester\n* Requirement for antihypertensive medication within one week of delivery\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* LV ejection fraction \\\u003C50% or history of clinical heart failure with reduced or preserved ejection fraction\n* Hypertrophic or other genetic cardiomyopathy\n* Hyperkalemia: potassium \\>5.3 mEq\u002FL\n* BMI at screening ≥50 kg\u002Fm2\n* Pre-pregnancy diabetes\n* Estimated glomerular filtration rate (eGFR) \\\u003C60mL\u002Fmin\u002F1.73 m2\n* Cirrhosis\n* Primary aldosteronism\n* Intention to become pregnant within 9 months\n* Active substance abuse\n* Other serious medical illnesses or concerns about protocol adherence\u002F mortality within 9 months\n* Participation in another interventional clinical study\n* Hypersensitivity to spironolactone\n* Addison's disease\n* Concomitant use of eplerenone or finerenone","FEMALE","18 Years",{"count":100,"type":101},204,"ESTIMATED","INTERVENTIONAL",[104],"PHASE2","The hypertensive disorders of pregnancy (preeclampsia and gestational hypertension) are associated with increased long-term maternal risk of developing cardiovascular disease. Recent evidence suggests that activation of the mineralocorticoid receptor promotes ongoing susceptibility to hypertension in women following hypertensive disorders of pregnancy. In addition, women with overweight\u002Fobesity are at increased risk for progression to chronic hypertension after experiencing hypertensive disorders of pregnancy. Among women with hypertensive disorders of pregnancy and pre-pregnancy overweight\u002Fobesity, the investigators will conduct a randomized trial to test the effect of pharmacologically blocking the mineralocorticoid receptor for three months after delivery on blood pressure and cardiac remodeling at nine months postpartum.",[107,108],"Preeclampsia","Gestational Hypertension",[110,111,112,113,114,115,116],"preeclampsia","gestational hypertension","spironolactone","blood pressure","hypertension","pregnancy","echocardiography","2026-04-02",{"date":119,"type":120},"2026-04-03","ACTUAL",{"date":122,"type":120},"2025-10-16",{"date":124,"type":101},"2029-03-02",{"name":5,"class":6},3]